Needham raised the firm’s price target on Liquidia (LQDA) to $32 from $25 and keeps a Buy rating on the shares. Friday’s ruling in a case over the ‘782 patent infringement denied the motion by United Therapeutics (UTHR) for a temporary restraining order and preliminary injunction that sought to enjoin Liquidia’s Yutrepia launch and eliminates the last potential hurdle that could have prevented Liquidia from launching Yutrepia, turning the focus on the program to execution, the analyst tells investors in a research note. The firm believes in the “underappreciated” differentiated clinical profile with better tolerability and higher dose levels” of Yutrepia and its best-in-class potential in a growing PAH/PH-ILD market opportunity, the firm added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Advances with YUTREPIA After Court Ruling
- Liquidia schedules first commercial shipment of YUTREPIA
- Liquidia Technologies: Strong Market Position and Growth Potential Amid Legal Clarity and Strategic Advancements
- Legal Victory and Promising Clinical Profile Boost Liquidia Technologies’ Market Prospects
- Liquidia price target raised to $37 from $36 at Scotiabank